Влияние дистальной полинейропатии на нарушение равновесия у больных сахарным диабетом
https://doi.org/10.21518/2079-701X-2013-12-118-119
Аннотация
Об авторах
О. С. ФедороваРоссия
И. В. Гурьева
Россия
И. А. Cтроков
Россия
Список литературы
1. Lafond D, Corriveau H, Prince F. Postural control mechanisms during quiet standing in patients with diabetic sensory neuropathy. Diabetes Care, 2004;27(1):173-178.
2. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia, 2000;43:957-973.
3. Cavanagh PR, Derr JA, Ulbrecht JS, Maser RE, Orchard TJ. Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus. Diabet Med., 1992;9:469-474.
4. Brach JS, Talkowski JB, Strotmeyer ES, Newman AB. Diabetes mellitus and gait dysfunction: possible explanatory factors. Physical therapy, 2008;88(11):1365-1374.
5. Centomo H, Termoz N, Savoie S, Beliveau L, Prince F. Postural control following a self-intiated reaching task in type 2 diabetic patients and age-matched controls. Gait & Posture, 2007;25:509-514.
6. Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford). 2012;51(Suppl 5):22-30.
7. Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford). 2012;51:600-9.
8. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 2012 Dec;51(12):2252-61.
9. Simsek I. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine? Bull NYUHosp Jt Dis, 2012;70:187-90.
10. Большая советская энциклопедия. М.: Советская энциклопедия. 1969-1978.
11. Kyttaris V. Kinase inhibitors: a new class of antirheumatic drugs. Drug Design. Development and Therapy, 2012;6:245-250.
12. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. DrugDiscov Today. 2010;15:517-530. Park SR, Speranza G, Piekarz R, et al. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol., 2013;71:981-90.
13. Nijjar JS, Tindell A, Mclnnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013;52:1556-62.
14. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-345.
15. Becker S, Groner B, Muller CW. Three-dimentional structure of the STAT3b homodimer bound to DNA. Nature, 1998;394:145-151.
16. Guschin D, Rogers N, Briscoe J, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 1995;14:1421-9.
Рецензия
Для цитирования:
Федорова ОС, Гурьева ИВ, Cтроков ИА. Влияние дистальной полинейропатии на нарушение равновесия у больных сахарным диабетом. Медицинский Совет. 2013;(12):118-119. https://doi.org/10.21518/2079-701X-2013-12-118-119
For citation:
Fedorova ОS, Gurieva IV, Strokov IA. The effect of distal polyneuropathy on balance disorder in patients with diabetes. Meditsinskiy sovet = Medical Council. 2013;(12):118-119. (In Russ.) https://doi.org/10.21518/2079-701X-2013-12-118-119